Evidence map›Paper›PMID 33563973›Full record

ArticleNature communications2021

p53 dynamics vary between tissues and are linked with radiation sensitivity.

Jacob Stewart-Ornstein, Yoshiko Iwamoto, Miles A Miller, Mark A Prytyskach, Stephane Ferretti, Philipp Holzer, Joerg Kallen, Pascal Furet, Ashwini Jambhekar, William C Forrester and 2 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 83 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. p53motifDB: integration of genomic information and tumour suppressor p53 binding motifs.Database : the journal of biological databases and curation · 2025
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Jacob Stewart-OrnsteinDepartment of Systems Biology and the Ludwig Center at Harvard, Blavatnik Institute at Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-8255-5904
Yoshiko IwamotoCenter for Systems Biology, Massachusetts General Hospital, Boston, MA, USA.
Miles A MillerCenter for Systems Biology, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0001-7638-8898
Mark A PrytyskachCenter for Systems Biology, Massachusetts General Hospital, Boston, MA, USA.
Stephane FerrettiNovartis Institutes for Biomedical Research, Basel, Switzerland.
Philipp HolzerNovartis Institutes for Biomedical Research, Basel, Switzerland.
Joerg KallenNovartis Institutes for Biomedical Research, Basel, Switzerland.
Pascal FuretNovartis Institutes for Biomedical Research, Basel, Switzerland.
Ashwini JambhekarDepartment of Systems Biology and the Ludwig Center at Harvard, Blavatnik Institute at Harvard Medical School, Boston, MA, USA.
William C ForresterChemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.ORCID 0000-0002-8640-8204
Ralph WeisslederDepartment of Systems Biology and the Ludwig Center at Harvard, Blavatnik Institute at Harvard Medical School, Boston, MA, USA. ralph_weissleder@hms.harvard.edu.
Galit LahavDepartment of Systems Biology and the Ludwig Center at Harvard, Blavatnik Institute at Harvard Medical School, Boston, MA, USA. galit@hms.harvard.edu.ORCID 0000-0003-4758-6427
Massachusetts General Hospital · USNovartis (Switzerland) · CHHarvard University · US

Funding

Dynamics of Signaling Pathways: Mechanism and FunctionR01GM083303 · NIGMS · HARVARD MEDICAL SCHOOL · PI LAHAV, GALIT · 2008 to 2020
$5.2M
Imaging of nanotherapeutic drug actionU01CA206997 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2017 to 2021
$2.9M
Imaging tumor associated macrophage (TAM) functionR01CA206890 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PITTET, MIKAEL, WEISSLEDER, MD, PHD, RALPH · 2017 to 2021
$1.9M
Dynamics of Cellular Senescence in Single CellsR01GM116864 · NIGMS · HARVARD MEDICAL SCHOOL · PI LAHAV, GALIT · 2017 to 2020
$1.6M
Defining and manipulating quiescence associated DNA damage resistance in single cellsR00CA207727 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI STEWART-ORNSTEIN, JACOB · 2019 to 2021
$735k
Defining and manipulating quiescence associated DNA damage resistance in single cellsK99CA207727 · NCI · HARVARD MEDICAL SCHOOL · PI STEWART-ORNSTEIN, JACOB · 2016 to 2017
$332k
NCI NIH HHS K99 CA207727NCI NIH HHS R00 CA207727NCI NIH HHS R01 CA206890NCI NIH HHS U01 CA206997NIGMS NIH HHS R01 GM083303NIGMS NIH HHS R01 GM116864
6 · The paper itself

Abstract

Radiation sensitivity varies greatly between tissues. The transcription factor p53 mediates the response to radiation; however, the abundance of p53 protein does not correlate well with the extent of radiosensitivity across tissues. Given recent studies showing that the temporal dynamics of p53 influence the fate of cultured cells in response to irradiation, we set out to determine the dynamic behavior of p53 and its impact on radiation sensitivity in vivo. We find that radiosensitive tissues show prolonged p53 signaling after radiation, while more resistant tissues show transient p53 activation. Sustaining p53 using a small molecule (NMI801) that inhibits Mdm2, a negative regulator of p53, reduced viability in cell culture and suppressed tumor growth. Our work proposes a mechanism for the control of radiation sensitivity and suggests tools to alter the dynamics of p53 to enhance tumor clearance. Similar approaches can be used to enhance killing of cancer cells or reduce toxicity in normal tissues following genotoxic therapies.

Indexed as

Radiation ToleranceAnimalsAntineoplastic AgentsCell Line, TumorCell SurvivalHumansMiceNeoplasmsProtein BindingProto-Oncogene Proteins c-mdm2Tissue DistributionTumor BurdenTumor Suppressor Protein p53Xenograft Model Antitumor AssaysAntineoplastic AgentsMdm2 protein, mouseProto-Oncogene Proteins c-mdm2Trp53 protein, mouseTumor Suppressor Protein p53

Identifiers

PMID33563973
PMCPMC7873198
OpenAlexW3128135611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.